Stock DNA
Pharmaceuticals: Major
USD 381 Million (Micro Cap)
NA (Loss Making)
NA
84.25%
-1.62
109.95%
-2.34
Revenue and Profits:
Net Sales:
60 Million
(Quarterly Results - Sep 2024)
Net Profit:
-38 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-36.85%
0%
-36.85%
6 Months
29.43%
0%
29.43%
1 Year
-32.16%
0%
-32.16%
2 Years
-89.46%
0%
-89.46%
3 Years
-73.14%
0%
-73.14%
4 Years
-87.25%
0%
-87.25%
5 Years
-86.28%
0%
-86.28%
Revance Therapeutics, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
201.03%
EBIT Growth (5y)
-1.22%
EBIT to Interest (avg)
-18.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.62
Sales to Capital Employed (avg)
0.54
Tax Ratio
0.84%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.34
EV to EBIT
-3.88
EV to EBITDA
-4.03
EV to Capital Employed
6.40
EV to Sales
2.61
PEG Ratio
NA
Dividend Yield
84.25%
ROCE (Latest)
-164.63%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2024
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 68 Schemes (46.97%)
Foreign Institutions
Held by 109 Foreign Institutions (28.78%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY
Sep'24
Sep'23
Change(%)
Net Sales
59.90
56.80
5.46%
Operating Profit (PBDIT) excl Other Income
-31.00
-42.00
26.19%
Interest
6.70
5.10
31.37%
Exceptional Items
0.00
-95.20
100.00%
Consolidate Net Profit
-38.10
-141.20
73.02%
Operating Profit Margin (Excl OI)
-538.70%
-776.50%
23.78%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2024 is 5.46% vs 95.86% in Sep 2023
Consolidated Net Profit
YoY Growth in quarter ended Sep 2024 is 73.02% vs -66.71% in Sep 2023
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
234.00
132.60
76.47%
Operating Profit (PBDIT) excl Other Income
-207.00
-238.40
13.17%
Interest
19.40
16.50
17.58%
Exceptional Items
-96.10
-70.80
-35.73%
Consolidate Net Profit
-324.00
-356.40
9.09%
Operating Profit Margin (Excl OI)
-943.10%
-2,053.10%
111.00%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 76.47% vs 70.44% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 9.09% vs -26.70% in Dec 2022
About Revance Therapeutics, Inc. 
Revance Therapeutics, Inc.
Pharmaceuticals: Major
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.
Company Coordinates 
Company Details
1222 Demonbreun Street, Suite 1001 , NASHVILLE TN : 37203
Registrar Details






